Disputes over pricing and distribution of asthma drugs
Patients are caught in the crossfire of conflicts between pharmaceutical companies and pharmacy benefit managers (PBMs), with no end in sight. the hill. GSK earlier this year stopped manufacturing fluticasone propionate (Flovent), the most common asthma inhaler for children, and instead offers an approved generic product that many PBMs do not cover. As drug companies and their PBMs clash over the pricing and distribution of these asthma drugs, patients face uncertainty and potential disruption to their treatment plans.
Navigating the regulatory landscape for artificial intelligence in healthcare
As artificial intelligence (AI) continues to revolutionize healthcare, the FDA's changing stance on regulating AI-powered medical technologies becomes increasingly important. politiko. While improvements in diagnosis and treatment are expected, concerns about safety, efficacy, and equitable access highlight the need for a balanced regulatory framework. Additionally, stakeholders across the healthcare ecosystem must navigate these complexities to harness the full potential of AI while ensuring patient safety and equitable healthcare outcomes. The FDA plans to ask Congress for new authority to regulate these technologies.
FDA gives green light to breakthrough treatment for food allergies
According to NPR, the FDA's recent approval of omalizumab (Xolair) to treat food allergies represents a major advance in addressing severe allergic reactions.. Omalizumab was previously approved to treat asthma and chronic hives, and this expansion offers hope to millions of people battling potentially life-threatening food allergies. As medical professionals prepare to incorporate omalizumab into treatment protocols, patients and advocates are hoping for new peace of mind and improved quality of life for people at risk of severe allergic reactions.
